Dashboard
Manage Tickers

PSNL Personalis, Inc.

Nasdaq personalis.com


$ 9.68 $ 0.23 (2.43 %)    

Friday, 24-Oct-2025 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 9.68
$ 9.73
$ 8.80 x 300
$ 10.00 x 1
$ 9.61 - $ 9.93
$ 2.83 - $ 10.95
823,491
na
858.39M
$ 1.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

btig-maintains-buy-on-personalis-raises-price-target-to-11
BTIG Maintains Buy on Personalis, Raises P...
10/22/2025 12:16:03

BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $6 to $11.

personalis-announces-phase-3-laura-trial-data-with-astrazeneca-showing-next-personal-mrd-test-effectively-assesses-post-crt-response-in-egfrm-stage-iii-nsclc
Personalis Announces Phase 3 LAURA Trial D...
10/16/2025 13:08:22

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

personalis-and-yale-cancer-center-collaboration-for-clinical-trial-titled-a-single-arm-phase-ii-trial-of-circulating-tumor-dna-guided-adjuvant-therapy-with-elacestrant-in-hormone-receptor-positive-her2-negative-breast-cancers-at-risk-for-late-recurrence-cate
Personalis And Yale Cancer Center Collabor...
09/10/2025 20:10:39

hc-wainwright--co-reiterates-buy-on-personalis-maintains-85-price-target
HC Wainwright & Co. Reiterates Buy on Pers...
09/08/2025 10:58:41

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...

personalis-announces-new-data-from-astrazeneca-phase-3-clinical-trial-in-lung-cancer-showing-personalis-mrd-test-next-personal-is-strong-predictor-of-outcomes-in-patients-with-stage-ii-iiib-egfr-mutated-nsclc-receiving-neoadjuvant-therapy
Personalis Announces New Data From Astraze...
09/03/2025 20:19:09

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

personalis-expands-va-million-veteran-program-work-with-new-135m-task-order-bringing-total-to-225m
Personalis Expands VA Million Veteran Prog...
08/22/2025 11:03:40

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 17:06:59

hc-wainwright--co-maintains-buy-on-personalis-lowers-price-target-to-85
HC Wainwright & Co. Maintains Buy on Perso...
08/06/2025 12:44:20

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price ta...

super-micro-computer-posts-downbeat-q4-results-joins-personalis-snap-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Super Micro Computer Posts Downbeat Q4 Res...
08/06/2025 12:11:55

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 12:08:40

why-astera-labs-shares-are-trading-higher-by-over-17-here-are-20-stocks-moving-premarket
Why Astera Labs Shares Are Trading Higher ...
08/06/2025 09:35:31

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/05/2025 21:07:20

personalis-lowers-fy2025-sales-guidance-from-80000m-90000m-to-70000m-80000m-vs-83326m-est
Personalis Lowers FY2025 Sales Guidance fr...
08/05/2025 20:03:14

Personalis (NASDAQ:PSNL) lowers FY2025 sales outlook from $80.000 million-$90.000 million to $70.000 million-$80.000 million vs...

personalis-sees-q3-sales-12000m-14000m-vs-18874m-est
Personalis Sees Q3 Sales $12.000M-$14.000M...
08/05/2025 20:02:45

Personalis (NASDAQ:PSNL) sees Q3 sales of $12.000 million-$14.000 million vs $18.874 million analyst estimate.

personalis-q2-eps-023-beats-024-estimate-sales-17203m-miss-20114m-estimate
Personalis Q2 EPS $(0.23) Beats $(0.24) Es...
08/05/2025 20:02:07

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

cramer-says-tesla-dominates-while-ouster-is-too-speculative
Cramer Says Tesla Dominates While Ouster I...
07/10/2025 12:07:44

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternat...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/09/2025 21:06:40

Core News & Articles
Personalis and Tempus Extend Partnership T...
07/09/2025 20:01:13

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer typesPersonalis, Inc. (NASDA...

personalis-presents-new-results-from-calla-phase-3-study-showing-for-first-time-ultrasensitive-next-personal-ctdna-blood-test-detected-cervical-cancer-progression-up-to-16-months-ahead-of-imaging
Personalis Presents New Results From CALLA...
06/03/2025 20:02:29

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION